Afatinib and Nivolumab for Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Previously Treated With Immunotherapy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 17 Jun 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 19 Dec 2018 Planned End Date changed from 1 Oct 2022 to 1 Nov 2022.
- 19 Dec 2018 Planned Primary Completion Date changed from 1 Oct 2021 to 1 Nov 2021.